MovDisordV3, PascalFrancis, Corpus, bibRecord, 002628

Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024)

Identifieur interne : 002628 ( PascalFrancis/Corpus ); précédent : 002627; suivant : 002629

Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024)

Auteurs : Brad A. Racette ; Mikula Stambuk ; Joel S. Perlmutter

Source :

Movement disorders [ 0885-3185 ] ; 2002.

RBID : Pascal:02-0584389

Descripteurs français

Pascal (Inist)
- Blépharospasme, Bontoxilysin, Résistance traitement, Secondaire, Etude cas, Traitement, Homme, Chimiothérapie.

English descriptors

KwdEn :
- Blepharospasm, Bontoxilysin, Case study, Chemotherapy, Human, Secondary, Treatment, Treatment resistance.

Abstract

We report on a patient with cranio-cervical dystonia injected with the new, lower protein formulation of botulinum toxin A who developed secondary resistance to this toxin. Subsequent injections with botulinum toxin B provided substantial reduction of blepharospasm. This is the first reported case of secondary resistance to the new preparation of botulinum toxin A.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 17`
A06				`@2 5`
A08	`01`	`1`	`ENG`	`@1 Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024)`
A11	`01`	`1`		`@1 RACETTE (Brad A.)`
A11	`02`	`1`		`@1 STAMBUK (Mikula)`
A11	`03`	`1`		`@1 PERLMUTTER (Joel S.)`
A14	`01`			`@1 Department of Neurology and Neurological Surgery (Neurology), Washington University School of Medicine @2 St. Louis, Missouri @3 USA @Z 1 aut. @Z 2 aut. @Z 3 aut.`
A14	`02`			`@1 American Parkinson Disease Association Advanced Center for Parkinson Research @2 St. Louis, Missouri @3 USA @Z 1 aut. @Z 3 aut.`
A14	`03`			`@1 Huntington Disease Society of America Center of Excellence @2 St. Louis, Missouri @3 USA @Z 1 aut. @Z 3 aut.`
A14	`04`			`@1 Department of Anatomy and Neurobiology, Washington University School of Medicine @2 St. Louis, Missouri @3 USA @Z 3 aut.`
A14	`05`			`@1 Mallinckrodt Institute of Radiology, Washington University School of Medicine @2 St. Louis, Missouri @3 USA @Z 3 aut.`
A20				`@1 1098-1100`
A21				`@1 2002`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000105152380380`
A44				`@0 0000 @1 © 2002 INIST-CNRS. All rights reserved.`
A45				`@0 10 ref.`
A47	`01`	`1`		`@0 02-0584389`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	`@0 We report on a patient with cranio-cervical dystonia injected with the new, lower protein formulation of botulinum toxin A who developed secondary resistance to this toxin. Subsequent injections with botulinum toxin B provided substantial reduction of blepharospasm. This is the first reported case of secondary resistance to the new preparation of botulinum toxin A.`
C02	`01`	`X`		`@0 002B09D`
C02	`02`	`X`		`@0 002B02C`
C03	`01`	`X`	`FRE`	`@0 Blépharospasme @5 01`
C03	`01`	`X`	`ENG`	`@0 Blepharospasm @5 01`
C03	`01`	`X`	`SPA`	`@0 Blefaroespasmo @5 01`
C03	`02`	`X`	`FRE`	`@0 Bontoxilysin @2 FE @2 FR @5 04`
C03	`02`	`X`	`ENG`	`@0 Bontoxilysin @2 FE @2 FR @5 04`
C03	`02`	`X`	`SPA`	`@0 Bontoxilysin @2 FE @2 FR @5 04`
C03	`03`	`X`	`FRE`	`@0 Résistance traitement @5 07`
C03	`03`	`X`	`ENG`	`@0 Treatment resistance @5 07`
C03	`03`	`X`	`SPA`	`@0 Resistencia tratamiento @5 07`
C03	`04`	`X`	`FRE`	`@0 Secondaire @5 08`
C03	`04`	`X`	`ENG`	`@0 Secondary @5 08`
C03	`04`	`X`	`SPA`	`@0 Secundario @5 08`
C03	`05`	`X`	`FRE`	`@0 Etude cas @5 16`
C03	`05`	`X`	`ENG`	`@0 Case study @5 16`
C03	`05`	`X`	`SPA`	`@0 Estudio caso @5 16`
C03	`06`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`06`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`06`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`07`	`X`	`FRE`	`@0 Homme @5 20`
C03	`07`	`X`	`ENG`	`@0 Human @5 20`
C03	`07`	`X`	`SPA`	`@0 Hombre @5 20`
C03	`08`	`X`	`FRE`	`@0 Chimiothérapie @5 23`
C03	`08`	`X`	`ENG`	`@0 Chemotherapy @5 23`
C03	`08`	`X`	`SPA`	`@0 Quimioterapia @5 23`
C07	`01`	`X`	`FRE`	`@0 Metalloendopeptidases @2 FE`
C07	`01`	`X`	`ENG`	`@0 Metalloendopeptidases @2 FE`
C07	`01`	`X`	`SPA`	`@0 Metalloendopeptidases @2 FE`
C07	`02`	`X`	`FRE`	`@0 Peptidases @2 FE`
C07	`02`	`X`	`ENG`	`@0 Peptidases @2 FE`
C07	`02`	`X`	`SPA`	`@0 Peptidases @2 FE`
C07	`03`	`X`	`FRE`	`@0 Hydrolases @2 FE`
C07	`03`	`X`	`ENG`	`@0 Hydrolases @2 FE`
C07	`03`	`X`	`SPA`	`@0 Hydrolases @2 FE`
C07	`04`	`X`	`FRE`	`@0 Enzyme`
C07	`04`	`X`	`ENG`	`@0 Enzyme`
C07	`04`	`X`	`SPA`	`@0 Enzima`
C07	`05`	`X`	`FRE`	`@0 Oeil pathologie @5 37`
C07	`05`	`X`	`ENG`	`@0 Eye disease @5 37`
C07	`05`	`X`	`SPA`	`@0 Ojo patología @5 37`
C07	`06`	`X`	`FRE`	`@0 Paupière pathologie @5 38`
C07	`06`	`X`	`ENG`	`@0 Eyelid disease @5 38`
C07	`06`	`X`	`SPA`	`@0 Párpado patología @5 38`
N21				`@1 343`
N82				`@1 PSI`

Format Inist (serveur)

NO :	PASCAL 02-0584389 INIST
ET :	Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024)
AU :	RACETTE (Brad A.); STAMBUK (Mikula); PERLMUTTER (Joel S.)
AF :	Department of Neurology and Neurological Surgery (Neurology), Washington University School of Medicine/St. Louis, Missouri/Etats-Unis (1 aut., 2 aut., 3 aut.); American Parkinson Disease Association Advanced Center for Parkinson Research/St. Louis, Missouri/Etats-Unis (1 aut., 3 aut.); Huntington Disease Society of America Center of Excellence/St. Louis, Missouri/Etats-Unis (1 aut., 3 aut.); Department of Anatomy and Neurobiology, Washington University School of Medicine/St. Louis, Missouri/Etats-Unis (3 aut.); Mallinckrodt Institute of Radiology, Washington University School of Medicine/St. Louis, Missouri/Etats-Unis (3 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2002; Vol. 17; No. 5; Pp. 1098-1100; Bibl. 10 ref.
LA :	Anglais
EA :	We report on a patient with cranio-cervical dystonia injected with the new, lower protein formulation of botulinum toxin A who developed secondary resistance to this toxin. Subsequent injections with botulinum toxin B provided substantial reduction of blepharospasm. This is the first reported case of secondary resistance to the new preparation of botulinum toxin A.
CC :	002B09D; 002B02C
FD :	Blépharospasme; Bontoxilysin; Résistance traitement; Secondaire; Etude cas; Traitement; Homme; Chimiothérapie
FG :	Metalloendopeptidases; Peptidases; Hydrolases; Enzyme; Oeil pathologie; Paupière pathologie
ED :	Blepharospasm; Bontoxilysin; Treatment resistance; Secondary; Case study; Treatment; Human; Chemotherapy
EG :	Metalloendopeptidases; Peptidases; Hydrolases; Enzyme; Eye disease; Eyelid disease
SD :	Blefaroespasmo; Bontoxilysin; Resistencia tratamiento; Secundario; Estudio caso; Tratamiento; Hombre; Quimioterapia
LO :	INIST-20953.354000105152380380
ID :	02-0584389

Links to Exploration step

Pascal:02-0584389

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024)</title>
<author><name sortKey="Racette, Brad A" sort="Racette, Brad A" uniqKey="Racette B" first="Brad A." last="Racette">Brad A. Racette</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology and Neurological Surgery (Neurology), Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>American Parkinson Disease Association Advanced Center for Parkinson Research</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Huntington Disease Society of America Center of Excellence</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stambuk, Mikula" sort="Stambuk, Mikula" uniqKey="Stambuk M" first="Mikula" last="Stambuk">Mikula Stambuk</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology and Neurological Surgery (Neurology), Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Perlmutter, Joel S" sort="Perlmutter, Joel S" uniqKey="Perlmutter J" first="Joel S." last="Perlmutter">Joel S. Perlmutter</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology and Neurological Surgery (Neurology), Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>American Parkinson Disease Association Advanced Center for Parkinson Research</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Huntington Disease Society of America Center of Excellence</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Department of Anatomy and Neurobiology, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Mallinckrodt Institute of Radiology, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">02-0584389</idno>
<date when="2002">2002</date>
<idno type="stanalyst">PASCAL 02-0584389 INIST</idno>
<idno type="RBID">Pascal:02-0584389</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002628</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024)</title>
<author><name sortKey="Racette, Brad A" sort="Racette, Brad A" uniqKey="Racette B" first="Brad A." last="Racette">Brad A. Racette</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology and Neurological Surgery (Neurology), Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>American Parkinson Disease Association Advanced Center for Parkinson Research</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Huntington Disease Society of America Center of Excellence</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stambuk, Mikula" sort="Stambuk, Mikula" uniqKey="Stambuk M" first="Mikula" last="Stambuk">Mikula Stambuk</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology and Neurological Surgery (Neurology), Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Perlmutter, Joel S" sort="Perlmutter, Joel S" uniqKey="Perlmutter J" first="Joel S." last="Perlmutter">Joel S. Perlmutter</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology and Neurological Surgery (Neurology), Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>American Parkinson Disease Association Advanced Center for Parkinson Research</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Huntington Disease Society of America Center of Excellence</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Department of Anatomy and Neurobiology, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Mallinckrodt Institute of Radiology, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2002">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Blepharospasm</term>
<term>Bontoxilysin</term>
<term>Case study</term>
<term>Chemotherapy</term>
<term>Human</term>
<term>Secondary</term>
<term>Treatment</term>
<term>Treatment resistance</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Blépharospasme</term>
<term>Bontoxilysin</term>
<term>Résistance traitement</term>
<term>Secondaire</term>
<term>Etude cas</term>
<term>Traitement</term>
<term>Homme</term>
<term>Chimiothérapie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We report on a patient with cranio-cervical dystonia injected with the new, lower protein formulation of botulinum toxin A who developed secondary resistance to this toxin. Subsequent injections with botulinum toxin B provided substantial reduction of blepharospasm. This is the first reported case of secondary resistance to the new preparation of botulinum toxin A.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>17</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024)</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>RACETTE (Brad A.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>STAMBUK (Mikula)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>PERLMUTTER (Joel S.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology and Neurological Surgery (Neurology), Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>American Parkinson Disease Association Advanced Center for Parkinson Research</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Huntington Disease Society of America Center of Excellence</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Anatomy and Neurobiology, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Mallinckrodt Institute of Radiology, Washington University School of Medicine</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s1>1098-1100</s1>
</fA20>
<fA21><s1>2002</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000105152380380</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2002 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>10 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>02-0584389</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>We report on a patient with cranio-cervical dystonia injected with the new, lower protein formulation of botulinum toxin A who developed secondary resistance to this toxin. Subsequent injections with botulinum toxin B provided substantial reduction of blepharospasm. This is the first reported case of secondary resistance to the new preparation of botulinum toxin A.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B09D</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B02C</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Blépharospasme</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Blepharospasm</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Blefaroespasmo</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Bontoxilysin</s0>
<s2>FE</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Résistance traitement</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Treatment resistance</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Resistencia tratamiento</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Secondaire</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Secondary</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Secundario</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Etude cas</s0>
<s5>16</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Case study</s0>
<s5>16</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Estudio caso</s0>
<s5>16</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>23</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>23</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>23</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Metalloendopeptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Peptidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Enzyme</s0>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Enzyme</s0>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Enzima</s0>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Oeil pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Eye disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Ojo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Paupière pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Eyelid disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Párpado patología</s0>
<s5>38</s5>
</fC07>
<fN21><s1>343</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 02-0584389 INIST</NO>
<ET>Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024)</ET>
<AU>RACETTE (Brad A.); STAMBUK (Mikula); PERLMUTTER (Joel S.)</AU>
<AF>Department of Neurology and Neurological Surgery (Neurology), Washington University School of Medicine/St. Louis, Missouri/Etats-Unis (1 aut., 2 aut., 3 aut.); American Parkinson Disease Association Advanced Center for Parkinson Research/St. Louis, Missouri/Etats-Unis (1 aut., 3 aut.); Huntington Disease Society of America Center of Excellence/St. Louis, Missouri/Etats-Unis (1 aut., 3 aut.); Department of Anatomy and Neurobiology, Washington University School of Medicine/St. Louis, Missouri/Etats-Unis (3 aut.); Mallinckrodt Institute of Radiology, Washington University School of Medicine/St. Louis, Missouri/Etats-Unis (3 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2002; Vol. 17; No. 5; Pp. 1098-1100; Bibl. 10 ref.</SO>
<LA>Anglais</LA>
<EA>We report on a patient with cranio-cervical dystonia injected with the new, lower protein formulation of botulinum toxin A who developed secondary resistance to this toxin. Subsequent injections with botulinum toxin B provided substantial reduction of blepharospasm. This is the first reported case of secondary resistance to the new preparation of botulinum toxin A.</EA>
<CC>002B09D; 002B02C</CC>
<FD>Blépharospasme; Bontoxilysin; Résistance traitement; Secondaire; Etude cas; Traitement; Homme; Chimiothérapie</FD>
<FG>Metalloendopeptidases; Peptidases; Hydrolases; Enzyme; Oeil pathologie; Paupière pathologie</FG>
<ED>Blepharospasm; Bontoxilysin; Treatment resistance; Secondary; Case study; Treatment; Human; Chemotherapy</ED>
<EG>Metalloendopeptidases; Peptidases; Hydrolases; Enzyme; Eye disease; Eyelid disease</EG>
<SD>Blefaroespasmo; Bontoxilysin; Resistencia tratamiento; Secundario; Estudio caso; Tratamiento; Hombre; Quimioterapia</SD>
<LO>INIST-20953.354000105152380380</LO>
<ID>02-0584389</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002628 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002628 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:02-0584389
   |texte=   Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024)
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024)

Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024)

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri